A landmark donation to support McGill University’s renowned genomics research and education programs from UK-based alumnus and long-time donor Victor Dahdaleh is a catalyst for advancements in genomics research. Thanks to gifts from Mr. Dahdaleh totalling more than $30 million, McGill will launch the Victor Phillip Dahdaleh Institute of Genomic Medicine. Today’s announcement, which coincides with McGill’s annual Homecoming festivities, caps off more than a year of Bicentennial celebrations and transformative expressions of philanthropic support in honour of McGill’s 200th anniversary.
McGill has long been a leader in Canada and North America in the increasingly vital fields of RNA and genomics research. Mr. Dahdaleh’s investment will further cement the University’s international leadership in genomics, while enabling the Institute to expand its high-impact research programs, invest in top talent, and train the next generation of world scientific leaders.
“On behalf of the McGill community, I would like to express my deep gratitude to Victor and Mona Dahdaleh for this visionary gift from a couple who have been great friends and loyal supporters of McGill for many years,” said Professor Christopher Manfredi, Interim Principal and Vice-Chancellor of McGill University. “Mr. Dahdaleh’s support will be a catalyst for advancements in genomics research that will improve health outcomes for communities around the world. Mr. Dahdaleh’s commitment to forging a healthier future through research is truly inspiring.”
Next-generation drug discovery research
The Institute will harness the interdisciplinary expertise and research infrastructure across McGill’s faculties to implement a full spectrum approach to genomic medicine, which draws on information from all of a person’s genes and how they interact to inform an individual’s clinical care. McGill researchers will lead breakthrough research aimed at the development of cutting-edge diagnostic tools, targeted treatments, and new pharmaceuticals and preventative vaccines. Additionally, the Institute’s integral social sciences pillar will draw on expertise across the University to lead important research on the ethical, policy, and legal implications of genomic medicine.
“It is an honour to contribute to McGill University’s world-leading genomics program,” said Mr. Dahdaleh. “I feel strongly that genomic medicine is the key to preventing, treating and one day curing many of the diseases that impact lives, families and communities around the world. I’m proud to be a part of this important effort to improve worldwide health.”
In concert with the Faculty of Medicine and Health Sciences and affiliated hospitals within the McGill University Health Centre, the Institute will maximize opportunities for clinical interventions in high-priority fields where McGill is already an established leader – such as cancer, neuroscience and mental health, chronic inflammatory diseases, and infectious diseases, including COVID-19.
“Mr. Dahdaleh’s generous gift provides crucial resources to help us attract impactful young scientists, students and trainees from around the world and create the conditions for these scientists to pursue their research activities and have a global impact on public health,” said Mark Lathrop, Director of the Institute. The gift will also provide important support for leveraging additional grant funding for the Institute.
Training students from diverse backgrounds
The Institute’s training program will have a particular focus on training students from lower- and middle- income countries, a goal that is especially important for Mr. Dahdaleh, who has directed many of his philanthropic efforts toward providing scholarships and training opportunities for disadvantaged students at world-class universities, including the London School of Economics.
Likewise, Mr. Dahdaleh’s investment in genomic medicine at McGill is an extension of his exceptional legacy of supporting innovative global health and health science research in Canada and internationally. He has previously given more than $20 million to establish the Dahdaleh Institute for Global Health Research at his alma mater York University in Toronto. He is also a longstanding supporter of the National Heart and Lung Institute at Imperial College London, the British Heart Foundation, and Asthma + Lung UK, where he has contributed to leading-edge research into cardiovascular disease and cancer, including mesothelioma.
“Mr. Dahdaleh shares McGill’s commitment to propelling innovation in genomic medicine on a global scale to improve diagnosis, treatment and preventative healthcare,” said Philippe Gros, Deputy Vice-Principal, Research and Innovation; Professor, Department of Biochemistry; and founder and co-lead of the McGill Research Centre on Complex Traits. “With his support, the Institute’s researchers will build new partnerships and deepen existing ties with leading genomics programs internationally, particularly in the UK, where McGill already works closely with researchers at the University of Oxford and Imperial College London, and Japan, where we share a joint PhD program with the University of Kyoto.”
This article was first published on 20 October by McGill University.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.